Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy

References

• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34)Lancet19983528548659742977
   PubMed Web of Science ®Google Scholar
• OhkuboYKishiwawaHArakiEIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year studyDiabetes Res Clin Pract1995281031177587918
   PubMed Web of Science ®Google Scholar
• NathanNMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyDiabetes Care20093219320318945920
   PubMed Web of Science ®Google Scholar
• BaylissWM SEThe mechanism of pancreatic secretionJ Physiol190228532535316992627
   PubMedGoogle Scholar
• ElrickH SLHladCJJrAraiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• McIntyreN HCTurnerDSNew interpretation of oral glucose toleranceLancet196427349202114149200
   PubMed Web of Science ®Google Scholar
• AzumaKRadikovaZMancinoJMeasurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetesJ Clin Endocrinol Metab200893245946418042650
   PubMed Web of Science ®Google Scholar
• WaniJH J-KJFonsecaVADipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic reviewCardiol Clin200826463964818929237
   PubMed Web of Science ®Google Scholar
• ChiaCW COKimWShinYKExogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetesDiabetes20095861342134919276444
   PubMed Web of Science ®Google Scholar
• DruckerDEnhancing incretin action for the treatment of type 2 diabetesDiabetes Care200326102929294014514604
   PubMed Web of Science ®Google Scholar
• NauckM SFEbertRCreutzfeldtWReduced incretin effect in type 2 (non-insulin-dependent) diabetesDiabetologia198629146523514343
   PubMed Web of Science ®Google Scholar
• AronoffSL BKShreinerBWantLGlucose metabolism and regulation: beyond insulin and glucagonDiabetes Spectrum2004173183190
   Google Scholar
• HolstJTherapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1Diabetes Metab Res Rev200218643044112469357
   PubMed Web of Science ®Google Scholar
• AhrenBPaciniGTuraAFoleyJESchweizerAImproved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetesHorm Metab Res2007391182682917992639
   PubMed Web of Science ®Google Scholar
• RazIHanefeldMXuLEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia200649112564257117001471
   PubMed Web of Science ®Google Scholar
• MuJ WJZhouYPRoyRSChronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetesDiabetes20065561695170416731832
   PubMed Web of Science ®Google Scholar
• GreenBDFlattPBaileyCDipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetesDiabetes Vas Dis Res200633159165
   PubMedGoogle Scholar
• LambeirADurinxCScharpeŚDe MeesterIDipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IVCritl Rev Clin Lab Sci2003403209294
   PubMed Web of Science ®Google Scholar
• AytacUDangNHCD26/Dipeptidyl Peptidase IV: A regulator of immune function and a potential molecular target for therapyCurr Drug Targets200441118
   Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKLerchCDipeptidyl peptidase-4(DPP-4) inhibitors for type 2 diabetes mellitusCochrane Database Syst Rev20084162CD00673918425967
   PubMed Web of Science ®Google Scholar
• LankasGRLeitingBRoyRSDipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes potential importance of selectivity over dipeptidyl peptidases 8 and 9Diabetes2005542988299416186403
   PubMed Web of Science ®Google Scholar
• HolstJJDeaconCFInhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetesDiabetes199847166316709792533
   PubMed Web of Science ®Google Scholar
• KirbyMYuDO’ConnorSGorrellMInhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibitionClin Sci2010118314119780719
   PubMed Web of Science ®Google Scholar
• BergmanAJStevensCZhouYPharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteersClin Ther2006281557216490580
   PubMed Web of Science ®Google Scholar
• HermanGAStevensCVan DyckKPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesClin Pharmacol Ther20051278667568816338283
   PubMed Web of Science ®Google Scholar
• HermanGABergmanALiuFPharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsJ Clin Pharmacol2006846887688616855072
   PubMed Web of Science ®Google Scholar
• HeHTranPYinHAbsorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humansDrug Metab Dispos200937353654419074975
   PubMed Web of Science ®Google Scholar
• Onglyza (saxagliptin) full prescribing information [Cited 2009 Oct 26]. Available from: http://packageinserts.bms.com/pi/pi_onglyza.pdf.
   Google Scholar
• ChanJCScottRArjona FerreiraJCSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab200810754555518518892
   PubMed Web of Science ®Google Scholar
• BergmanAJ CJYiBMarburyTEffect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitorDiabetes Care20073071862186417468348
   PubMed Web of Science ®Google Scholar
• RosenstockJBrazgRAndryukPJLuKSteinPSitagliptin Study GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther200628101556156817157112
   PubMed Web of Science ®Google Scholar
• HermanGABergmanAYiBKipnesMThe Sitagliptin Study GroupTolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesCurr Med Res Opin200622101939194717022853
   PubMed Web of Science ®Google Scholar
• MistryGCBergmanAJLuoWLMultiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjectsJ Clin Pharmacol200747215916417244766
   PubMed Web of Science ®Google Scholar
• MistryGCBergmanAJZhengWSitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjectsBr J Clin Pharmacol72008661364218503607
   PubMed Web of Science ®Google Scholar
• MohanVYangWSonHYEfficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and KoreaDiabetes Res Clin Pract200983110611619097665
   PubMed Web of Science ®Google Scholar
• NonakaKKakikawaTSatoAEfficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetesDiabetes Res Clin Pract200879229129817933414
   PubMed Web of Science ®Google Scholar
• HeYLFlanneryBCampestriniJEffect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteersCurr Med Res Opin200824617031703918471347
   PubMed Web of Science ®Google Scholar
• HeYLSaboRCampestriniJThe effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteersBr J Clin Pharmacol200865333834617961192
   PubMed Web of Science ®Google Scholar
• HeYLSaboRPicardFStudy of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetesCurr Med Res Opin20092551265127219364302
   PubMed Web of Science ®Google Scholar
• SerraDHeYLBullockJEvaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetesInt J Clin Pharmacol Ther200846734936418793589
   PubMed Web of Science ®Google Scholar
• HeYLLigueros-SaylanMSunkaraGVildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjectsJ Clin Pharmacol2008481859517986525
   PubMed Web of Science ®Google Scholar
• AyalasomayajulaSPDoleKHeYLEvaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjectsCurr Med Res Opin200723122913292017931461
   PubMed Web of Science ®Google Scholar
• HeYLSaboRSunkaraGEvaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteersJ Clin Pharmacol2007478998100417660482
   PubMed Web of Science ®Google Scholar
• HeYLSaboRRiviereGJEffect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsCurr Med Res Opin20072351131113817519080
   PubMed Web of Science ®Google Scholar
• HuPYinQDeckertFPharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteersJ Clin Pharmacol2009491394918832295
   PubMed Web of Science ®Google Scholar
• RosenstockJAguilar-SalinasCKleinENepalSListJChenRfor the CV181-011 Study InvestigatorsEffect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetesCurrent Medical Research and Opinion200925102401241119650754
   PubMed Web of Science ®Google Scholar
• ChristopherRCovingtonPDavenportMPharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjectsClin Ther200830351352718405789
   PubMed Web of Science ®Google Scholar
• HeiseTGraefe-ModyEUHüttnerSRingATrommeshauserDDugiKAPharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patientsDiabetes Obes Metab200911878679419476474
   PubMed Web of Science ®Google Scholar
• AmoriRLauJPittasAEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA2007298219420617622601
   PubMed Web of Science ®Google Scholar
• MonamiMIacomelliIMarchionniNMannucciEDipeptidyl-peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trialsNutr Metab Cardiovasc Dis200910.1016/j.numecd.2009.03.015
   Web of Science ®Google Scholar
• RazIChenYWuMEfficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesCurr Med Res Opin200824253755018194595
   PubMed Web of Science ®Google Scholar
• CharbonnelBKarasikALiuJWuMMeiningerGSitagliptin Study GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care200629122638264317130197
   PubMed Web of Science ®Google Scholar
• ScottRLoeysTDaviesMJEngelSSSitagliptin Study 801 GroupEfficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetesDiabetes Obes Metab2008101095996918201203
   PubMed Web of Science ®Google Scholar
• HermansenKKipnesMLuoEEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab200795733L74517593236
   PubMed Web of Science ®Google Scholar
• GoldsteinBJFeinglosMNLuncefordJKJohnsonJWilliams-HermanDESitagliptin 036 Study GroupEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care20073081979198717485570
   PubMed Web of Science ®Google Scholar
• NauckMAMeiningerGShengDTerranellaLSteinPPSitagliptin Study GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab20079219420517300595
   PubMed Web of Science ®Google Scholar
• DeFronzoRAOkersonTViswanathanPGuanXHolcombeJHMacConellLEffects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyCurr Med Res Opin200824102943295218786299
   PubMed Web of Science ®Google Scholar
• BosiECamisascaRPColloberCRochotteEGarberAJEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care200730489089517277036
   PubMed Web of Science ®Google Scholar
• AhrénBPaciniGFoleyJESchweizerAImproved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 yearDiabetes Care20052881936194016043735
   PubMed Web of Science ®Google Scholar
• GarberAJFoleyJEBanerjiMAEffects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaDiabetes Obes Metab200810111047105618284434
   PubMed Web of Science ®Google Scholar
• GarberAJSchweizerABaronMARochotteEDejagerSVildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab20079216617417300592
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDBaronMAChangIDejagerSAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia20075061148115517387446
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSMillsDSchweizerAComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care200730221722317259484
   PubMed Web of Science ®Google Scholar
• RosenstockJKimSWBaronMAEfficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab2007917518517300593
   PubMed Web of Science ®Google Scholar
• BolliGDottaFRochotteECohenSEEfficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind studyDiabetes Obes Metab2008101829018034842
   PubMed Web of Science ®Google Scholar
• PanCYangWBaronaJPComparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trialDiabet Med200825443544118341596
   PubMed Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEDejagerSComparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetesDiabet Med200724995596117509069
   PubMed Web of Science ®Google Scholar
• GokeBHershonKKerrDEfficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metforminHorm Metab Res2008401289289518726829
   PubMed Web of Science ®Google Scholar
• AschnerPKipnesMSLuncefordJKEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care200629122632263717130196
   PubMed Web of Science ®Google Scholar
• PratleyREJauffret-KamelSGalbreathEHolmesDTwelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetesHorm Metab Res200638642342816823726
   PubMed Web of Science ®Google Scholar
• RosenstockJSankohSListJFGlucose-lowering activity of the dipeptidyl-peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetesDiab Obes Metab200810376386
   PubMed Web of Science ®Google Scholar
• DeFronzoRHissaMGarberAFor the saxagliptin 014 study group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care20093291649165519478198
   PubMed Web of Science ®Google Scholar
• ChacraARTanGHApanovitchARavichandranSListJChenRfor the CV181-040 InvestigatorsSaxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trialInt J Clin Pract20096391395140619614786
   PubMed Web of Science ®Google Scholar
• JadzinksyMPfutznerAPaz-PachecoEXuZAllenEChenRfor the CV181-038 InvestigatorsSaxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trialDiab Obes Metab200911611622
   Web of Science ®Google Scholar
• NauckMAEllisGCFleckPRWilsonCAMekkiQfor the Alogliptin Study 008 GroupEfficacy and safety of adding the dipeptidyl-peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled studyInt J Clin Pract200963465519125992
   PubMed Web of Science ®Google Scholar
• PratleyREKipnesMSFleckPRWilsonCMekkiQon behalf of the Alogliptin Study 007 GroupEfficacy and safety of the dipeptidyl-peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapyDiab Obes Metab200911167176
   PubMed Web of Science ®Google Scholar
• RosenstockJRendellMSGrossJLFleckPRWilsonCAMekkiQAlogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemiaDiab Obes Metab200910.1111/j.1463-1326.2009.01124.x
   Web of Science ®Google Scholar
• Clinicaltrials.gov. Gov#NCT00915772. [Cited 2009 Oct 10].
   Google Scholar
• Clinicaltrials.gov. Gov#NCT00954447. [Cited 2009 Oct 10].
   Google Scholar
• HanefeldMHermanGAWuMMickelCSanchezMSteinPPSitagliptin Study 014 InvestigatorsOnce-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurr Med Res Opin20072361329133917559733
   PubMed Web of Science ®Google Scholar
• ScottRWuMSanchezMSteinPEfficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetesInt J Clin Pract200761117118017156104
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEvidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab200810111114112418355325
   PubMed Web of Science ®Google Scholar
• RisticSByiersSFoleyJHolmesDImproved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose responseDiabetes Obes Metab20057669269816219012
   PubMed Web of Science ®Google Scholar
• MariAScherbaumWANilssonPMCharacterization of the influence of vildagliptin on model-assessed cell function in patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab20081067568218248490
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJERendellMEffects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care20081311303517947341
   PubMed Web of Science ®Google Scholar
• D’AlessioDADenneyAMHermillerLMTreatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetesJ Clin Endocrinol Metab2009941818818957505
   PubMed Web of Science ®Google Scholar
• BaggioLLDruckerDJTherapeutic approaches to preserve islet mass in type 2 diabetesAnnu Rev Med20065726528116409149
   PubMed Web of Science ®Google Scholar
• MoritohYTakeuchiKAsakawaTKataokaOOdakaHCombining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db miceBrit J of Pharm20091573415426
   PubMed Web of Science ®Google Scholar
• MeeceJPancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapiesCurr Med Res Opin200723493394417407650
   PubMed Web of Science ®Google Scholar
• HermanGABergmanAStevensCEffect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetesJ Clin Endocrinol Metab2006914612461916912128
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPDEffects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetesDiabetes20075651475148017303799
   PubMed Web of Science ®Google Scholar
• Russell-JonesDMolecular, pharmacological, and clinical aspects of liraglutide, a once-daily human GLP-1 analogueMol Cell Endocrinol20092971–213714019041364
   PubMed Web of Science ®Google Scholar
• BuseJKlonoffDNielsenLMetabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trialClin Ther200729113915317379054
   PubMed Web of Science ®Google Scholar
• MatikainenNMänttäriSSchweizerAVildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesDiabetologia20064992049205716816950
   PubMed Web of Science ®Google Scholar
• MERCK. Januvia (sitagliptin) tablets. Available from: http://www.januvia.com/sitagliptin/januvia/consumer/index.jsp. [Cited 2009 October 8].
   Google Scholar
• Novartis Pharmaceuticals UK Ltd Galvus 50 mg tablets [online]. [Updated 2009 Sept; cited 2009 Oct 26]. Available from: http://www.emc.medicines.org.uk/medicine/20734/SPC/Galvus+50+mg+Tablets/.
   Google Scholar
• DeaconCMK-431 (Merck)Current Opinion in Investigational Drugs2005641942615898349
   PubMedGoogle Scholar
• FDA post-marketing drug safety information Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation-forPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. [Cited 2009 Sept 19].
   Google Scholar
• AhmadSR SJExenatide and rare adverse eventsN Engl J Med2008358181970197118456920
   PubMed Web of Science ®Google Scholar
• KoehlerJBaggioLLamontBAliSDruckerDGlucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in miceDiabetes2009582148216119509017
   PubMed Web of Science ®Google Scholar
• MatveyenkoAVDrySCoxHIBeneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metforminDiabetes20095871604161519403868
   PubMed Web of Science ®Google Scholar
• DoreDDSeegerJDArnold ChanKUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurr Med Res Opin20092541019102719278373
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/cder/guidance/index.htm. [Updated 2008 Dec; cited 2009 Oct 10].
   Google Scholar
• DhillonSWeberJSaxagliptinDrugs200969152103211419791828
   PubMed Web of Science ®Google Scholar
• TECOS-Studyorg [homepage on the Internet] University of Oxford; Trial Evaluating Cardiovascular Outcomes with Sitagliptin. [cited 2009 Oct 26.] Available from: http://www.tecos-study.org
   Google Scholar
• Pi-SunjerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetesDiabetes Res Clin Pract200776113213817223217
   PubMed Web of Science ®Google Scholar
• DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res200739321822317373638
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEfficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycemiaDiabetes Obes Metab200810867568218248490
   PubMed Web of Science ®Google Scholar